Quarterly Report

July - September 2026

Bio-Works

Bio-Works Technologies AB (publ)
Org. number: 556935-3559

The third quarter in review

Third quarter, July – September 2026

(July - September 2025)

- Net sales for the third quarter were 9.6 (16.6) MSEK.
- Operating profit for the quarter was -8.1 (-1.2) MSEK.
- Profit for the third quarter was -7.7 (-1.4) MSEK.
- Cash flow from operating activities amounted to 13.5 (-7.1) MSEK. The improvement is mainly attributable to increased advance payments and a reduction in operating receivables.
- Order intake for the third quarter totaled 40.8 (10.0) MSEK, an increase of 30.8 MSEK (order value converted at the exchange rate at the time of order).
- Personnel costs and other external costs totaled 15.4 (13.6) MSEK during the quarter.
- Earnings per share (before and after dilution) were -0.08 (-0.02) SEK.
- Cash and cash equivalents at the end of the period, as of September 30, stood at 43.8 (21.5) MSEK.

Year to date, January – September 2026

(January – September 2025)

- Net sales for the period were 59.0 (38.8) MSEK, an increase of 52%.
- Operating profit for the period was -7.0 (-16.6) MSEK.
- Profit for the first nine months of the year was -5.5 (-16.6) MSEK.
- Cash flow from operating activities amounted to 7.9 (–14.6) MSEK.
- Order intake for the period totaled 65.3 (68.9) MSEK.
- Personnel costs and other external costs for the period were 50.6 (44.4) MSEK.
- Earnings per share (before and after dilution) were -0.06 (-0.21) SEK.
- Cash and cash equivalents at the end of the period, as of September 30, stood at 43.8 (21.5) MSEK.

Significant events during the quarter

- On July 6, Bio-Works received an order worth approximately 8.9 MSEK from a recurring customer. The order relates to the delivery of Bio-Works chromatography products and further strengthens the ongoing collaboration between the parties. Delivery is scheduled for Q4 2027.

- On July 14, the seventh exercise period for Bio-Works warrants of series TO 2, issued in connection with the Company's rights issue of units in August 2024, ended. On July 15, the Company announced that a total of 403,058 TO 2 warrants had been exercised for the subscription of 403,058 new shares in the Company. Bio-Works thereby received proceeds of 403,058 SEK before issue costs.

- On July 17, Bio-Works received an order worth 22.6 MSEK from a recurring customer. The order relates to the Bio-Works chromatography products and further strengthens the ongoing collaboration between the parties. Delivery is scheduled for Q4 2026 and Q2 2027.

- On August 18, the Board of Directors of Bio-Works appointed Eva Lindskog as Chief Executive Officer, effective 1 November 2026. Eva Lindskog will succeed Lone Carlbom, who will continue in an operational role within the company and work alongside Eva Lindskog.

- On August 25, Bio-Works received an order from a major US biotechnology company that selected Bio-Works as a partner in the development of a new drug. The collaboration is in the development phase and involves the use of Bio-Works products and expertise in the purification of biologic drugs. The total order value is 2.8 MSEK.

Significant events after the end of the quarter

- On October 14, the eighth exercise period for Bio-Works warrants of series TO 2, issued in connection with the Company's rights issue of units in August 2024, ended. On October 15, the Company announced that a total of 558,776 TO 2 warrants had been exercised for the subscription of 558,776 new shares in the Company. Bio-Works thereby received proceeds of 558,776 SEK before issue costs.

Message from the CEO

Performance during the first nine months of the year shows that Bio-Works has made progress. Revenue has increased and the operating result has improved compared with the corresponding period last year. The third quarter was weaker in terms of deliveries and earnings, while order intake was strong.

During the quarter, we received several significant orders from returning customers. In addition, a major US biotechnology company selected Bio-Works as a partner in the development of a new biologic drug. This is an important example of how our products and technical expertise support our customers' drug development projects.

Several orders received during the quarter are scheduled for delivery in future periods and therefore did not contribute to revenue in the quarter. The time between order placement and delivery means that sales and earnings can vary between individual quarters. Performance therefore needs to be assessed over a longer period.

During the year, we have adapted our organisation to better meet customer needs and fulfil scheduled deliveries. These adjustments entail higher costs in the short term and have therefore affected earnings. At the same time, they put us in a better position to manage a growing business and deliver on the orders we have secured.

Our priority is to translate customer interest and existing orders into completed projects, revenue and an increasingly stable business.

Cash flow has strengthened, partly through advance payments from customers, and our earnings have improved. Personally, I am very pleased with this progress as I am preparing to hand over the role of CEO to Eva Lindskog in November. We will place greater emphasis on commercial efficiency, and I will continue to work in an operational role at Bio-Works, supporting continuity in customer relationships, operations and the company's continued development together with Eva.

Lone Carlbom
CEO Bio-Works Technologies AB

The Group

BIO-WORKS GROUP KEY PERFORMANCE INDICATORS	2026	2025	2026	2025	2025
Amount in KSEK	Jul-Sep	Jul-Sep	Jan-Sep	Jan-Sep	Jan-Dec
Net sales	9 649	16 635	58 979	38 761	62 502
Order intake	40 840	9 983	65 259	68 909	94 525
Operating profit/loss	-8 100	-1 233	-6 975	-16 624	-17 519
Profit/loss for the period	-7 737	-1 369	-5 540	-16 621	-15 247
Cash flow from operating activities	13 511	-7 086	7 864	-14 638	-18 811
Bank balance	43 812	21 521	43 812	21 521	34 932
Equity	45 708	30 044	45 708	30 044	49 206
Equity ratio (%)	65%	57%	65%	57%	70%
	2026	2025	2026	2025	2025
Earnings per share (SEK)	jul-sep	jul-sep	jan-sep	jan-sep	Jan-Dec
Share price per closing day	3,06	2,50	3,06	2,50	2,62
Earnings per share before dilution	-0,08	-0,02	-0,06	-0,21	-0,18
Earnings per share after dilution	-0,08	-0,02	-0,06	-0,21	-0,18
	2026	2025	2026	2025	2025
Number of shares	jul-sep	jul-sep	jan-sep	jan-sep	Jan-Dec
Number of shares period start	100 010 822	78 733 461	98 225 122	77 959 580	77 959 580
Number of shares period end	100 413 880	80 370 942	100 413 880	80 370 942	98 225 122
Average number of shares before dilution	100 343 783	80 068 364	99 796 798	78 868 664	82 762 634
Average number of shares after dilution	111 935 218	80 068 364	111 709 414	78 868 664	91 735 074

The Group – third quarter

Order intake

Order intake for the third quarter amounted to 40.8 (10.0) MSEK, an increase of 30.8 MSEK (with the order value translated at the exchange rate prevailing at the time of the order). Order intake may vary significantly between quarters, as Bio-Works is still in a growth phase.

Net sales

Net sales for the third quarter amounted to 9.6 (16.6) MSEK, a decrease of 7.0 MSEK. Net sales may vary significantly between quarters, as Bio-Works is still in a growth phase.

NET SALES BY GEOGRAPHIC MARKET	2026	2025	2026	2025	2025
Amount in KSEK	Jul-Sep	Jul-Sep	Jan-Sep	Jan-Sep	Jan-Dec
Europe	7 932	11 921	47 379	26 554	46 498
North America	1 709	3 764	7 522	7 976	10 181
Asia	8	950	4 078	4 231	5 823
Total	**9 649**	**16 635**	**58 979**	**38 761**	**62 502**

Earnings

Costs for raw materials and other consumables amounted to 2.4 (3.6) MSEK. Costs decreased compared with the corresponding quarter last year, mainly due to lower sales volumes.

Personnel costs amounted to 7.2 (6.7) MSEK. The increase in personnel costs was attributable to new hires and an increase in employees' working hours, in line with the company's continued expansion.

Other external costs amounted to a total of 8.2 (6.9) MSEK. Salaries for employees in certain countries outside Sweden are classified as consultancy fees and are therefore included in other external expenses.

Total personnel costs and other external costs thus amounted to 15.4 (13.6) MSEK during the quarter.

Depreciation remained unchanged during the quarter and amounted to 0.1 (0.1) MSEK.

Operating profit for the quarter amounted to -8.1 (-1.2) MSEK. The deterioration in the operating result compared with the corresponding quarter last year was mainly due to lower net sales combined with higher personnel costs and other external expenses. Lower costs for raw materials and consumables partially offset this development.

Profit for the quarter amounted to -7.7 (-1.4) MSEK.

Earnings per share (before and after dilution) amounted to -0.08 (-0.02) SEK.

Financing and cash flow

Cash flow from operating activities amounted to 13.5 (-7.1) MSEK. The improvement compared with the third quarter last year was mainly attributable to increased advance payments from customers for future deliveries. A reduction in operating receivables also contributed positively to cash flow for the quarter. Cash flow can vary significantly between quarters depending on the timing of customer payments and deliveries.

Cash flow from financing activities amounted to 0.4 (1.6) MSEK. The exercise of TO2 warrants had an impact on cash flow during the quarter, net of issue costs.

Cash flow for the period amounted to 13.7 (-5.7) MSEK.

Cash and cash equivalents at the end of the period, as of September 30, amounted to a total of 43.8 (21.5) MSEK.

The company assesses that its operations are financed for at least the next 12 months.

The Group – year to date

Order intake

Order intake for the period amounted to a total of 65.3 (68.9) MSEK, a decrease of 3.6 MSEK (with the order value translated at the exchange rate prevailing at the time of the order).

Net sales

Net sales for the period amounted to 59.0 (38.8) MSEK, an increase of 20.2 MSEK. Sales growth was strong during the period, primarily driven by large deliveries in Europe.

NET SALES BY GEOGRAPHIC MARKET	**2026**	**2025**	**2026**	**2025**	**2025**
Amount in KSEK	**Jul-Sep**	**Jul-Sep**	**Jan-Sep**	**Jan-Sep**	**Jan-Dec**
Europe	7 932	11 921	47 379	26 554	46 498
North America	1 709	3 764	7 522	7 976	10 181
Asia	8	950	4 078	4 231	5 823
Total	**9 649**	**16 635**	**58 979**	**38 761**	**62 502**

Earnings

Costs for raw materials and other consumables amounted to 15.1 (9.4) MSEK.

Personnel costs amounted to 24.9 (22.5) MSEK. The increase in personnel costs was attributable to new hires and an increase in employees' working hours.

Other external costs amounted to a total of 25.6 (21.9) MSEK. Salaries for employees in certain countries outside Sweden are classified as consultancy fees and are therefore included in other external expenses.

Total personnel costs and other external costs thus amounted to 50.6 (44.4) MSEK during the period.

Depreciation and amortisation during the period amounted to 0.4 (0.4) MSEK.

Operating profit for the period amounted to -7.0 (-16.6) MSEK. Despite the weaker third quarter, the operating result for the first nine months of the year improved by 9.6 MSEK compared with the corresponding period last year. Higher net sales contributed to the improvement, while increased operating expenses limited earnings growth.

Profit for the period amounted to -5.5 (-16.6) MSEK.

Earnings per share (before and after dilution) amounted to -0.06 (-0.21) SEK.

Financing and cash flow

Cash flow from operating activities amounted to 7.9 (-14.6) MSEK. The improvement compared with the corresponding period last year was attributable to an improved operating result and more favourable changes in working capital. In particular, a reduction in operating receivables contributed positively to cash flow, while inventory build-up had a smaller negative impact than in the previous year.

Cash flow from financing activities amounted to 1.9 (2.3) MSEK.

Cash flow for the period amounted to 8.8 (-12.6) MSEK.

Cash and cash equivalents at the end of the period, as of September 30, amounted to a total of 43.8 (21.5) MSEK.

The company assesses that its operations are financed for at least the next 12 months.

The share & shareholders

- Bio-Works has been listed on Spotlight Stock Market since July 18, 2024, where the share is traded under the ticker BIOWKS. The ISIN code for the share is SE0007387089.
- Warrants issued in connection with the rights issue in Q3 2024 are traded under the designation BIOWKS TO2 with ISIN code SE0022574109. Subscription for new shares by exercise of warrants can take place quarterly during the first ten (10) trading days of each quarter from Q1 2025 up to and including Q3 2027, on a total of eleven (11) occasions. The subscription price is 1.00 SEK. Upon full exercise of all warrants of series TO2, the company may receive a total of 39 MSEK before issue costs (approximately).

Number of shares December 31, 2025	98,225,122
Number of shares September 30, 2026	100,413,880
Number of warrants TO2 – December 31, 2025	18,714,248
Number of warrants TO2 – September 30, 2026	16,525,490

As of September 30, 2026, Bio-Works had 2,239 shareholders (2,177 as of December 31, 2025).

The ten largest shareholders in Bio-Works as of September 30, 2026 are presented in the table below.

Shareholders	Number of shares	Share of votes
SWEDIA INVEST AB	22 297 439	22,21%
CALYPTRA AB	18 477 172	18,40%
AVANZA PENSION	4 811 921	4,79%
FÄRJSUNDET INDUSTRI AKTIEBOLAG / PETER EHRENHEIM	3 852 969	3,84%
BONIT INVEST AB	3 490 005	3,48%
DARIUSH HOSSEINIAN	2 694 490	2,68%
FUTUR PENSION	2 657 221	2,65%
NORDNET PENSIONSFÖRSÄKRING AB	1 649 150	1,64%
MOLANDER, KARL EDVIN	1 450 036	1,44%
SIX SIS AG, ZüRICH	1 407 242	1,40%
Ten largest shareholders	**62 787 645**	**62,53%**
Other shareholders	37 626 235	37,47%
Total	**100 413 880**	**100,00%**

As of September 30, 2026, 16,525,490 warrants are outstanding as shown in the tables below.

Warrants Q3 2024, rights issue				
Series	**Exercise period**	**Exercise price SEK**	**Outstanding 2025-12-31**	**Outstanding 2026-09-30**
TO2	Q1 2025 to Q3 2027	1.00	18 714 248	16 525 490

If all outstanding warrants are exercised, this would result in an increase in share capital of 1,652,549 SEK.

Employees

During the third quarter of 2026, the average number of employees in Bio-Works amounted to 32.7 (29.0), and the number of full-time equivalent employees was 32.2 (26.8). At the end of the period, the number of employees was 33 (29), of whom 48.5% were men and 51.5% were women.

Accounting and valuation principles

The annual report and interim reports are prepared in accordance with the Swedish Annual Accounts Act and BFNAR 2012:1 (K3). The accounting principles applied are unchanged compared with the previous year.

Financial reports

Group

GROUP INCOME STATEMENT Amount in KSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
OPERATING INCOME					
Net sales	9 649	16 635	58 979	38 761	62 502
Change in inventory	316	-583	677	-321	-200
Other operating income	71	43	682	318	607
TOTAL OPERATING INCOME	**10 037**	**16 095**	**60 339**	**38 758**	**62 909**
OPERATING EXPENSES					
Raw materials and consumables	-2 392	-3 570	-15 104	-9 411	-14 501
Other external expenses	-8 244	-6 867	-25 637	-21 901	-32 332
Personnel costs	-7 188	-6 684	-24 943	-22 513	-31 883
Depreciation of assets	-141	-132	-392	-381	-512
Other operating costs	-172	-75	-1 238	-1 176	-1 200
TOTAL OPERATING EXPENSES	**-18 136**	**-17 328**	**-67 313**	**-55 382**	**-80 428**
OPERATING PROFIT / LOSS	**-8 100**	**-1 233**	**-6 975**	**-16 624**	**-17 519**
INTEREST INCOME, EXPENSE AND SIMILAR ITEMS					
Interest earnings and similar sources of income	172	-61	482	246	550
Interest costs and similar expenses	216	-67	1 024	-217	-193
TOTAL INTEREST INCOME, EXPENSE AND SIMILAR ITEMS	**388**	**-128**	**1 506**	**29**	**357**
PROFIT / LOSS BEFORE TAX	**-7 712**	**-1 361**	**-5 469**	**-16 595**	**-17 163**
Income tax	-25	-8	-71	-25	1 916
NET PROFIT / LOSS	**-7 737**	**-1 369**	**-5 540**	**-16 621**	**-15 247**
EARNINGS PER SHARE (before dilution)	**-0,08**	**-0,02**	**-0,06**	**-0,21**	**-0,18**
EARNINGS PER SHARE (after dilution)	**-0,08**	**-0,02**	**-0,06**	**-0,21**	**-0,18**

GROUP BALANCE SHEET	2026	2025	2025
Amount in KSEK	30 sep	30 sep	31 dec
ASSETS			
Fixed assets			
Tangible fixed assets	2 344	1 637	1 710
Total fixed assets	**2 344**	**1 637**	**1 710**
Current assets			
Inventory	16 017	13 689	15 642
Accounts receivable	3 813	9 939	12 694
Tax receivables	435	0	0
Other short-term receivables	1 546	2 809	3 034
Prepaid expenses and accrued income	2 690	2 969	2 744
Cash and bank balances	43 812	21 521	34 932
Total current assets	68 312	50 927	69 046
TOTAL ASSETS	**70 656**	**52 563**	**70 756**
EQUITY AND LIABILITIES			
Equity			
Share capital	10 041	8 037	9 823
Other contributed capital	399 527	381 777	397 806
Other equity incl. profit for the period	-363 861	-359 771	-358 422
Total equity	**45 708**	**30 044**	**49 206**
Short-term liabilities			
Accounts payable	2 899	4 450	4 091
Customer prepayments	16 680	14 719	10 013
Other short-term liabilities	2 976	1 524	1 123
Accrued expenses and deferred incomes	2 394	1 826	6 323
Total liabilities	**24 949**	**22 518**	**21 549**
TOTAL EQUITY AND LIABILITIES	**70 656**	**52 563**	**70 756**

GROUP CASH FLOW STATEMENT Amount in KSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
CASH FLOW FROM OPERATING ACTIVITIES					
Operating profit / loss	-8 100	-1 233	-6 975	-16 624	-17 519
Adjustments to cash flow from operating activities:					
Depreciation and amortization	141	132	392	381	512
Currency effects	215	-67	1 024	-216	-192
Interest received	172	-61	482	246	550
Interest paid	0	0	0	-1	-1
Taxes paid	-25	-8	-71	-25	1 916
CASH FLOW FROM OPERATING ACTIVITIES BEFORE WORKING CAPITAL CHANGES	**-7 597**	**-1 237**	**-5 148**	**-16 239**	**-14 735**
WORKING CAPITAL CHANGES					
Increase (-)/Decrease (+) in inventory	241	-1 220	-375	-3 625	-5 578
Increase (-)/Decrease (+) in operating receivables	4 550	-6 441	9 989	-9 381	-12 136
Increase (+)/Decrease (-) in operating liabilities	16 319	1 812	3 399	14 607	13 638
CASH FLOW FROM OPERATING ACTIVITIES	**13 511**	**-7 086**	**7 864**	**-14 638**	**-18 811**
INVESTMENT ACTIVITIES					
Sale of tangible assets	0	0	0	0	0
Investments in tangible assets	-133	-201	-1 026	-201	-404
CASH FLOW FROM INVESTMENT ACTIVITIES	**-133**	**-201**	**-1 026**	**-201**	**-404**
FINANCING ACTIVITIES					
New share issue through exercise of warrants	403	1 637	2 189	2 411	20 263
Share issue costs	-48	-52	-248	-140	-181
CASH FLOW FROM FINANCING ACTIVITIES	**355**	**1 585**	**1 941**	**2 271**	**20 082**
CASH FLOW THIS PERIOD	**13 733**	**-5 700**	**8 779**	**-12 567**	**866**
Liquidity at the beginning of the period	30 045	27 236	34 932	34 279	34 279
Exchange rate differences	33	-15	101	-191	-213
LIQUIDITY AT THE END OF THE PERIOD	**43 812**	**21 521**	**43 812**	**21 521**	**34 932**

GROUP CHANGE IN EQUITY Amount in KSEK	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Equity at the beginning of the period	49 206	44 584	44 584
New share issue as a result of warrant conversion	2 189	2 411	20 263
Share issue costs	-248	-140	-181
Translation differences	101	-191	-213
Profit / loss for the period	-5 540	-16 621	-15 247
EQUITY AT THE END OF THE PERIOD	**45 708**	**30 044**	**49 206**

Parent company

PARENT COMPANY INCOME STATEMENT Amount in KSEK	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
OPERATING INCOME	**95**	**182**	**1 509**	**549**	**2 392**
OPERATING EXPENSES					
Other external expenses	-411	-1 153	-2 221	-2 846	-4 220
Personnel costs	-299	-214	-602	-658	-871
TOTAL OPERATING EXPENSES	**-710**	**-1 367**	**-2 823**	**-3 504**	**-5 091**
OPERATING PROFIT / LOSS	**-615**	**-1 184**	**-1 314**	**-2 954**	**-2 699**
PROFIT / LOSS FROM FINANCIAL ITEMS					
Profit / loss from shares in Group companies	-3 119	-6 228	-9 186	-12 687	-17 990
Interest earnings and similar sources of income	107	15	372	247	485
Interest costs and similar expenses	0	0	0	0	0
TOTAL PROFIT / LOSS FROM FINANCIAL ITEMS	**-3 012**	**-6 212**	**-8 814**	**-12 440**	**-17 506**
PROFIT / LOSS BEFORE TAX	**-3 627**	**-7 397**	**-10 128**	**-15 394**	**-20 204**
Income tax	0	0	0	0	2 000
NET PROFIT / LOSS	**-3 627**	**-7 397**	**-10 128**	**-15 394**	**-18 204**

PARENT COMPANY BALANCE SHEET	2026	2025	2025
Amount in KSEK	30 sep	30 sep	31 dec
ASSETS			
Fixed assets			
Financial assets	182	182	182
Total fixed assets	**182**	**182**	**182**
Current assets			
Other short-term receivables	50	437	0
Prepaid expenses and accrued income	549	610	336
Cash and bank balances	22 498	15 355	31 449
Total current assets	**23 097**	**16 403**	**31 785**
TOTAL ASSETS	**23 279**	**16 585**	**31 967**
EQUITY AND LIABILITIES			
EQUITY			
Share Capital	10 041	8 037	9 823
Other contributed capital	399 527	381 777	397 806
Retained earnings	-376 941	-358 736	-358 736
Profit/loss for the period	-10 128	-15 394	-18 204
TOTAL EQUITY	**22 500**	**15 685**	**30 687**
Short-term liabilities			
Accounts payable	121	610	219
Other short-term liabilities	299	0	199
Accrued expenses and deferred incomes	360	290	862
Total short-term liabilities	**779**	**900**	**1 280**
TOTAL EQUITY AND LIABILITIES	**23 279**	**16 585**	**31 967**

Risks

Operational risks

Bio-Works' operations and market are subject to a number of risks that are wholly or partly beyond the Group's control and that affect, or may affect, Bio-Works' operations, financial position, and results. The risk factors below are presented in no particular order and are not intended to be exhaustive.

Business risks

Bio-Works is in a commercialization phase, which entails risks that sales revenues may vary significantly from quarter to quarter. This is due to a relatively small number of larger customers whose needs are difficult to predict. As the number of larger customers increases, this variation is expected to decrease.

Environmental risks

Bio-Works' production operations are subject to environmental regulations and require notification under the Swedish Environmental Code. This means that Bio-Works is exposed to the risk of incurring damages or costs related to remediation, clean-up, or monitoring of environmental issues. Bio-Works holds permits for handling flammable goods.

Financial risks

It is the company's assessment that the company's operations are financed for at least the next 12 months.

Geopolitical factors

Geopolitical tensions in parts of the world have led to increased uncertainty. This increased uncertainty affects both the global economy and supply chains, which may have long-term effects.

The Board's declaration

The Board of Directors and the Chief Executive Officer certify that, to the best of their knowledge, the interim report provides a fair overview of the parent company's and the Group's operations, financial position, and results, and describes the most significant risks and uncertainties facing the parent company and its subsidiaries.

Bio-Works provides no forecasts.

Uppsala, October 30, 2026

Peter von Ehrenheim	Chairman of the board
Peter Nählstedt	Board member
Thomas Gür	Board member
Jonas Ahlén	Board member
Eva Lindskog	Board member
Andrea Ballagi	Board member
Lone Carlbom	CEO

This report has not been reviewed by the company's auditor.

Financial calendar

Year-end report Jan – Dec 2026	February 19, 2027

This English translation is unofficial and is provided for convenience.

All reports are available on the Bio-Works website from the specified date.

For further information
Please visit the Bio-Works homepage at, www.bio-works.com or contact
Arne Hauge CFO
e-mail: info@bio-works.com / arne.hauge@bio-works.com
phone: +46(0)8-502 705 83.